** It Also Expects to See an M&a Rally This Year, With Some $57 Billion of Unallocated Cash Available for M&a and Business Development for the Companies It CoversCorrects Ric for Merck & Co in Bullet 6
更正默沙东的第6条内容
** in Its 2025 Pharma Outlook, Berenberg Says Obesity Drugs Will Dominate Pipeline News, While Stock-Specific Problems in China Should Begin to Ease
** 在其2025年的制药展望中，贝伦贝格表示肥胖药物将主导管道资讯，而中国特定股票问题预计将开始缓解
** It Sees Sales Growth of 26% for Obesity Drug Makers, With Emerging Oral Treatments Under Close Watch, and Slower Growth for Those Not Exposed to Weight Loss Treatments
** 它预计肥胖药物制造商的销售增长将达到26%，新兴口服治疗方案将受到密切关注，而未接触减肥治疗的公司的增长将较慢
** It Also Expects to See an M&a Rally This Year, With Some $57 Billion of Unallocated Cash Available for M&a and Business Development for the Companies It Covers
** 它还预计今年将看到并购的反弹，约570亿的未分配现金可用于其覆盖公司的并购和业务发展
** "It Is Clear That R&D Budgets Are Increasing and External Pipeline Assets Remain an Essential Component to Support Top Lines" - Berenberg
** "显然研发预算正在增加，外部管道资产仍然是支持收入的重要组成部分" - 贝伦贝格
** Stocks Exposed to the U.S. Vaccines Market Should See Some Improvement Once the Achievability of the Trump Administration's Plans Is Better Understood, Berenberg Adds
** 接触美国疫苗市场的股票，一旦特朗普政府计划的可实现性得以更好理解，应该会有所改善，贝伦贝格补充道
** Its "Buy" Choices for 2025 Include Eli Lilly Lly.n, AstraZeneca Azn.l, GSK Gsk.l, Merck & Co Mrk.n And Sanofi Sasy.pa
** 它为2025年选择的"买入"股票包括礼来公司 丽.n，阿斯利康 Azn.l，葛兰素史克 Gsk.l，默沙东 Mrk.n 和 赛诺菲安万特 Sasy.pa
** It Remains "Hold" on Novo Nordisk Novob.co, Roche Rog.s, Pfizer Pfe, Bristol-Myers Bmy.n, Novartis Novn.s and Abbvie Abbv.n
** 对诺和诺德保持 "持有" Novob.co, 罗氏 Rog.s, 辉瑞 Pfe, 布里斯托-迈尔斯 Bmy.n， 诺华 Novn.s 和 艾伯维公司 Abbv.n
(Reporting by Vera Dvorakova)
（通讯报道：Vera Dvorakova）
((Vera.dvorakova@Thomsonreuters.com))
（(Vera.dvorakova@Thomsonreuters.com)）
